4-C-Alkyl/aryl-S-ribosylhomocysteine (SRH) analogues were prepared by coupling of homocysteine with 4-substituted ribofuranose derivatives. The diastereoselective incorporation of the methyl substituent into the 4 position of the ribose ring was accomplished by the addition of methylmagnesium bromide to the protected ribitol-4-ulose yielding the 4-C-methylribitol in 85% yield as single 4R diastereomer. The 4-C hexyl, octyl, vinyl, and aryl ribitols were prepared analogously. Chelation controlled addition of a carbanion to ketones from the Si-face was responsible for the observed stereochemical outcome. Oxidation of the primary alcohol of the 4-C ribitols with catalytic amounts of tetrapropylammonium perruthenate in the presence of N-methylmorpholine N-oxide produced 4-C-alkylribono-1,4-lactones in high yields. Mesylation of the latter compounds at the 5-hydroxyl position and treatment with a protected homocysteine thiolate afforded protected 4-C-alkyl/aryl-SRH analogues as the lactones. Reduction with lithium triethylborohydride and successive global deprotections with TFA afforded 4-C-alkyl/aryl SRH analogues. These analogues might impede the S-ribosylhomocysteinase(LuxS)-catalyzed reaction by preventing β-elimination of a homocysteine molecule, and thus depleting the production of quorum sensing signaling molecule AI-2.
Introduction
Quorum sensing (QS) is a process in which exchange of chemical signals enables bacterial population to take control of crucial functions in united communities for enhancement of symbiosis, virulence, and biofilm formation. [1] [2] [3] [4] The interference in this chemical communication among bacteria could result in improving our control of bacterial infection.
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Numerous small and macromolecules that modulate QS pathways have been designed and synthesized. [5] [6] [7] [8] The acetylhomoserine-based isothiocyanate and haloacetamide probes, which covalently inhibit bacterial QS [9] and probes for signaling molecules which utilize 'click chemistry', [10] have been developed. The S-ribosylhomocysteinase (LuxS; EC 4.4.1.21 ) is a key enzyme in the biosynthetic pathway for conversion of S-ribosyl-l-homocysteine (SRH, 1; Figure 1 ) to homocysteine (Hcy) and 4,5-dihydroxy-2,3-pentadione (DPD), the precursor for the type II autoinducer (AI-2) [11] which mediates the interspecies QS among bacteria (see Figure 2) . [12] [13] [14] Various SRH analogues have been designed as mechanistic probes and/or inhibitors of the LuxS enzyme. [6] Among them, one of the most important are SRH analogues that target mechanistic steps of the LuxS catalytic cycle by effecting the initial ring opening step (e.g. 1-deoxy-SRH analog 2 [15] and [4-aza] -3a [16] or 4-[thio]-SRH analogs 3b [17] ; i.e. 1 → intermediate A, Figure 2 ) or one of the tautomerization/isomerization steps (A → B or B → C). These included substrates lacking the enolizable hydroxyl group at C3 (e.g. 4; X = H or OMe), [18] including mechanistically significant C3 halogenated [3-Br or F]-SRH analogues 4. [19] Zhou and co-workers synthesized substrate analogue Shomoribosyl-l-cysteine 5, which was designed to prevent the final mechanistic step of the LuxS catalytic cycle. [15] Moreover, brominated furanone derivatives were found to modify LuxS selectively leading to the covalent inhibition. [20] The substitution of hydrogen at C4 by an alkyl or aryl group in SRH (e.g. 18) should impede the LuxS-catalyzed reaction by preventing β-elimination of a homocysteine molecule (i.e. C → D) since abstraction of the C4-proton by a general base (e.g. Glu158) from the intermediate C, when R = alkyl/aryl, will be disallowed ( Figure 2) . Consequently, the formation of DPD necessary for the production of AI-2 would be depleted with 4-C-alkyl-SRH analogues.
Since LuxS forms a dimer it is possible that the size and chemical nature of the group incorporated at C4 of the ribose ring might also play an additional role in inhibiting dimerization. Recently, the SRH analogues having the sterically demanding alkyl or aryl group at the Hcy fragment of the SRH have been designed and were attempted to be synthesized. [21] These analogues were thought to be able to bind to one monomer of the LuxS protein while blocking the correct association of the second monomer, possibly interfering with dimerization interfaces. [21] [22] [23] In theory, for example, the longer the alkyl chain incorporated at the C4 position in analogs 18, the more potent the inhibition of dimerization of LuxS might be observed since the inhibitor can reach both homodimer parts of the protein. The inhibitor might also block one monomer leading to the alteration of the activity and as a consequence conformational changes of the second monomer. Herein, we report synthesis of [4-alkyl/aryl]-SRH analogues which would deplete the production of AI-2 by preventing elimination of Hcy and could also act as dimerization inhibitors.
Results and discussion
The 4-C-alkyl/aryl-S-ribosylhomocysteine analogues were prepared by coupling of the homocysteine with the 4-C-substituted ribofuranose derivatives. The 4-C-substituted riboses can be prepared either by manipulation of natural carbohydrates [24] or the chemoenzymatic strategy from non-sugar precursors. [25, 26] From the method available, we chose Maddaford's method for diastereoselective incorporation of the alkyl substituent into the 4 position of the D-ribose ring by the addition of Grignard reagents to 4-ulose. [24] Reduction of the protected ribose 6 with NaBH 4 provided the acyclic ribitol 7 (Scheme 1). Regioselective silylation of the primary hydroxyl with TBDMSCl and subsequent DessMartin or Collins oxidation of the secondary hydroxyl in 8 yielded ketone 9. The overall yield for the conversion of the ribose to the ribitol-4-ulose 9 [27] was 75% (5 steps).
Treatment of ketone 9 with methylmagnesium bromide at −78°C produced the 4-C-methylribitol 4R-10a in 85% yield as a single isomer after purification by silica gel chromatography. The addition of the hexylmagnesium bromide or octylmagnesium bromide to ketone 9 gave the corresponding 4-C-hexyl and 4-C-octyl ribitols 10b and 10c in 74% and 69% isolated yields, respectively. The 4-C-vinyl ribitol 10d (61%) and 4-C-aryl ribitol 10e (96%) were prepared analogously. The Grignard reagent addition to the ribitol-4-ulose 9, which is an α-alkoxy ketone, is proposed to proceed via a 5-membered ring chelate [28] with the complexation of the metal with the carbonyl group and the α-alkoxy group at C3 allowing transfer of the alkanide carbanion in the anti-fashion (Si-face) to the α-alkoxy group at C3. [24, 29] Treatment of the 4-C-methylribitol 10a with TBAF (0°C/30 min) effected desilylation to give ribitol 11a (78%). Analogous deprotection of 10b-e produced the 4-C-substituted ribitols 11b-e (75-87%) with a primary hydroxyl group at C1 and a tertiary hydroxyl group at C4. For the ring closure, we elected the oxidation of the primary alcohol at C1 to the carboxylic acid with the concomitant ring closure to the corresponding ribono-1,4-lactones, [30, 31] since such an approach would provide convenient precursors for the synthesis of both 4-C-substituted SRH lactones [32] and, after reduction, 4-Calkyl/aryl SRH analogues. Thus, oxidation (6 h) of the 11a with a catalytic amount of tetrapropylammonium perruthenate (TPAP) in the presence of a stoichiometric amount of N-methylmorpholine N-oxide (NMO) [33, 34] gave the corresponding 4-C-methylribono-1,4-lactone 12a (80%). The formation of lactone was supported by the disappearance of the signals for H1 and H1 protons ( 1 H NMR) and the appearance of a peak at 172.1 ppm for the carbonyl carbon at C1 ( 13 C NMR). Oxidation of 4-C-hexyl and 4-C-octyl ribitols 11b or 11c with TPAP/NMO also proceeded smoothly to give the 4-C-hexyl-and 4-Coctylribonolactones 12b and 12c (95%). The longer reaction time (e.g. 14 h), especially with substrates with long alkyl chain (e.g. 11c), led to the formation of by-product(s) ( ∼ 30%). The 4-C-vinyl 12d and 4-C-aryl 12e lactones were obtained analogously by the oxidation of 11d and 11e, respectively.
Detritylation of 12a (6 h, rt) with TFA/CH 2 Cl 2 gave 13a (66%). Analogous treatment of the hexyl 12b and octyl 12c with TFA (5 h, rt) gave ribono-1,4-lactones 13b and 13c in 80% and 75% yields, respectively. The longer reaction time should be avoided since the formation of by-product(s) was observed during detritylation of 12b to 13b when the reaction was carried out for 16 h. [35] Treatment of the vinyl analogue 12d with TFA (5 h, rt) also gave detritylated ribonolactone 13d but only in 35% yield after purification on silica gel column chromatography. Similarly, 4-C-aryl analogues 12e were converted to 13e (70%).
Careful reduction of the protected 4-C-hexyl ribonolactone 12b with LiEtBH 3 (−20°C, 30 min) gave lactol 14b as an anomeric mixture (α/β, 1:3) in 54% yield after column chromatography. The chemical shifts for the anomeric protons and the magnitude of vicinal 3 J H1-H2 coupling constants were diagnostic [36, 37] for the determination of the composition of α/β anomers. The anomeric proton for α-isomer [5. 61 ppm (dd, J = 4.2, 11.5 Hz)] appeared as doublet of doublets with splitting to H2 and OH group, while H1 proton for β-anomer appears upfield as a doublet [5.15 ( 
Next, the coupling of the selected ribono-1,4-lactones 13 with homocysteine was examined. Thus, treatment of 13b, 13c, or 13e with methylsulfonyl chloride gave the primary 5-O-mesyl derivatives 15b, 15c, and 15e (60-83%). From different approaches [13, 15, [38] [39] [40] tested for the nucleophilic displacement of the mesylate in 15 with homocysteine thiolates, we found that reactions with the (N-Boc, COOtBu) protected homocysteine, generated in situ by the reduction of the corresponding homocystine [13] with water-extractable tris(2-carboxyethyl)phosphine [18] gave the best results. Thus, treatment of the 15b with homocysteine thiolate (3 equiv) generated from BocNHCH(CH 2 CH 2 SH)CO 2 t-Bu/LDA afforded protected 4-C-hexyl-SRH lactone 16b (65%, Scheme 2). Analogous coupling of 15c with Hcy gave 16c, contaminated with the protected Hcy substrate ( ∼ 1:1), which was directly used in the subsequent deprotection step. 4-C-Aryl mesylate 15e was coupled with homocysteine thiolate to give 16e (48%). It is noteworthy to add that displacement of the primary mesylate (or tosylate) from the highly branching ribonolactones 15 having trisubstituted carbon (C4) at the adjacent position needs to be carried out with great caution to avoid the formation of by-products. The structure of one such by-product isolated from the reaction of 15c with Hcy was tentatively assigned as the 2,3-O-isopropylidene-4-C-octyl-D-ribono-1,5-lactone (see note under the experimental procedure for 17c) based on the spectroscopic analysis ( 1 H and 13 C NMR and HRMS) and by comparison with the similar ribono-1,5-lactones. [41] Treatment of 16b with TFA effected global removal of the N-Boc, acetonide and tbutyl ester protecting groups to give 4-C-hexyl-SRH lactone 17b in 55% yield after HPLC purification. Analogous treatment of the crude 16c with TFA and purification of the resulting mixture on the Sep-Pak column gave 4-C-octyl-SRH lactone 17c in 21% overall yield from 15c. Deprotection of 16e gave 4-C-(4-methoxyphenyl)-SRH lactone 17e (75%).
Synthesis of the somehow unstable 4-C-alkyl/aryl-SRH derivatives 19 was accomplished by the reduction of either protected 16 or deprotected 17 lactones with lithium triethylborohydride. Thus, treatment of 17c with LiEt 3 BH/THF (2 equiv.) in CH 2 Cl 2 at −20°C effected reduction of the lactone yielding 4-C-octyl SRH 19c (α/β, ∼ 1:3; 60%). Alternatively, reduction of the protected 4-C-hexyl-SRH lactone 16b with LiEt 3 BH followed by deprotection of the resulting 18b with TFA and TFA/H 2 O afforded 4-C-hexyl-SRH 19b (α/β, 1:9; 75%). Similarly, subjection of 16e to the reduction and deprotection sequence afforded 4-C-(4-methoxyphenyl)-SRH 19e (α/β, 1:9; 77%).
Conclusion
We have developed synthesis of S-ribosylhomocysteine analogues substituted at the ribosyl C-4 position with the alkyl or aryl group. The critical steps in this multistep synthesis starting from ribose were (i) diasteroselective addition of the alkyl/aryl-magnesium bromides to protected ribitol-4-ulose to produce the 4-C-alky/aryl-ribitols in high yields as single 4R diastereomers, (ii) oxidation of the primary alcohol at C1 of the 4-C substituted ribitols with the catalytic amounts of tetrapropylammonium perruthenate in the presence of a stoichiometric amount of N-methylmorpholine N-oxide to give 4-C-alkyl/aryl-ribono-1,4-lactones in good yields, (iii) displacement of 5-mesylate with the protected homocysteine thiolate to afford protected 4-C-alkyl/aryl-SRH analogues with a lactone carbonyl at the C1 position, and (iv) reduction with lithium triethylborohydride and successive global deprotections with TFA to give 4-C-alkyl/aryl-SRH analogues. Enzymatic and biological properties of these novel analogues of SRH will be published elsewhere.
Experimental section

General procedures
The 1 H (400 or 600 MHz) and 13 C (100 MHz) NMR spectra were determined with solutions in CDCl 3 unless otherwise noted. Mass spectra (MS) and HRMS were obtained in the AP-ESI or TOF-ESI mode. TLC was performed with Merck kieselgel 60-F 254 sheets, products were detected with 254 nm light or by visualization with the Ce(SO 4 [XTerra preparative RP 18 OBD column (5 μm 19 × 150 mm) with a gradient program using CH 3 CN/H 2 O as a mobile phase] or Sep-Pak cartridge (C18 classic column) using water and ethanol as eluting system. Reagent grade chemicals were used, and solvents were dried by reflux over and distillation from CaH 2 (except for THF/potassium) under argon. The 4-C-substituted SRH analogues need to be handled with care and stored in a refrigerator ( ∼ 4°C) in solid or dried oil state.
2,3-O-Isopropylidene-5-O-tritylribitol (7)
NaBH 4 (91 mg, 2.4 mmol) was added to a stirred solution of 6 [42] (865 mg, 2.0 mmol) in EtOH (20 mL) at 0°C (ice bath) under N 2 atmosphere. After 1 h, the reaction mixture was partitioned between NaHCO 3 /H 2 O and EtOAc. The organic layer was dried over anhydrous MgSO 4 
1-O-tert-Butyldimethysilyl-2,3-O-isopropylidene-5-O-tritylribitol (8)
TBDMSCl (302 mg, 2.0 mmol) and imidazole (204 mg, 3.0 mmol) were added to a solution of 7 (652 mg, 1.5 mmol) in DMF (10 mL) at room temperature and stirring was continued for 72 h. The volatiles were evaporated and the residue was partitioned between saturated NH 4 Cl/H 2 O and EtOAc. The separated organic layer was then washed with NaHCO 3 /H 2 O, dried over Mg 2 SO 4 , evaporated and the resulting residue was column chromatographed (50% hexane/EtOAc) to give 8 [24] (666 mg, 81%) as an amorphous white powder: 1 
1-O-tert-Butyldimethysilyl-2,3-O-isopropylidene-5-O-tritylribitol-4-ulose (9)
Method A. The Dess-Martin reagent (2.35 mL of 15 wt% solution/CH 2 Cl 2 ; 381 mg, 0.9 mmol) was added to a solution of 8 (330 mg, 0.6 mmol) in CH 2 Cl 2 (8 mL) at room temperature and stirred for 3 h. The reaction mixture was partitioned between saturated NaHCO 3 (10 mL)/dilute Na 2 S 2 O 3 (5 mL) and CH 2 Cl 2 (15 mL). The organic layer was dried over anhydrous MgSO 4 and evaporated. The residue was column chromatographed (85% hexane/EtOAc) to give 9 [24] (300 mg, 91%) as an oil: 1 (8 mL) at ambient temperature. The resulting mixture was stirred for 1 h and was immediately column chromatographed (EtOAc) to give 9 (185 mg, 93%) with spectra properties as above.
General procedure for the synthesis of 4-C-substituted ribitols 10
RMgBr reagent (0.75 mmol) was added to a stirred solution of 9 (205 mg, 0.375 mmol) in anhydrous THF (5 mL) at −78°C under N 2 atmosphere. After 15 min, the reaction mixture was allowed to warm up to ambient temperature and was kept stirring for 2 h. The reaction was then quenched by the addition of MeOH (1 mL) and diluted with EtOAc (15 mL). The resulting mixture was washed with 0.1 N HCl and the organic layer dried over anhydrous MgSO 4 . Volatiles were evaporated and the crude residue was then purified by flash column chromatography (90% hexane/EtOAc).
1-O-tert-Butyldimethysilyl-2,3-O-isopropylidene-4-C-methyl-5-O-tritylribitol
(10a) Treatment of 9 (205 mg, 0.375 mmol) with MeMgBr (1 M/THF, 0.75 mL, 0.75 mmol), using the procedure reported in Section 4.5, gave 10a [24] (180 mg, 85%) as an clear oil: 1 
1-O-tert-Butyldimethysilyl-4-C-hexyl-2,3-O-isopropylidene-5-O-tritylribitol
(10b) Treatment of 9 (165 mg, 0.30 mmol) with n-C 6 H 13 MgBr (0.8 M/THF; 0.75 mL, 0.6 mmol), using the procedure reported in Section 4.5 (flash column chromatography; 80% hexane/EtOAc), gave 10b (140 mg, 74%) as a clear oil: 1 
1-O-tert-Butyldimethysilyl-2,3-O-isopropylidene-4-C-octyl-5-O-tritylribitol
(10c) Treatment of 9 (480 mg, 0.87 mmol) with n-C 8 H 17 MgBr (2 M/THF; 0.87 mL, 1.74 mmol), using the procedure reported in Section 4. 4.6.2. 2,3-O-Isopropylidene-4-C-hexyl-5-O-tritylribitol (11b 
1-O-tert-
2,3-O-Isopropylidene-4-C-octyl-5-O-tritylribitol (11c)
Treatment of 10c (350 mg, 0.52 mmol) with TBAF, using the procedure reported in Section 4.6, gave 11c (200 mg, 84%) as a viscous oil. 1 
2,3-O-Isopropylidene-4-C-vinyl-5-O-tritylribitol (11d)
Treatment of 10d (200 mg, 0.34 mmol) with TBAF, using the procedure reported in Section 4.6, gave 11d (124 mg, 77%) as a viscous oil: 1 
2,3-O-Isopropylidene-4-C-4-methoxyphenyl-5-O-tritylribitol (11e)
Treatment of 10e (190 mg, 0.29 mmol) with TBAF, using the procedure reported in Section 4.6, gave 11e (117 mg, 75%) as a viscous oil: 1 General procedure for the synthesis of 4-C-substituted ribono-1,4-lactones 12 N-Methylmorpholine N-oxide (NMO; 50 mg, 0.42 mmol) and tetrapropylammonium perruthenate (TPAP; 1 mg, 0.002 mmol) were added to a stirred solution of 11 (0.11 mmol) in CH 2 Cl 2 (3.5 mL) at ambient temperature under N 2 atmosphere. After 6 h, the reaction mixture was filtered off and the filtrate was dried over MgSO 4 and evaporated. The residue was purified by flash column chromatography (75 → 50% hexane/EtOAc) to give 12.
Note: Treatment of 11 with NMO and TPAP, as described above, in the presence of 4 Å molecular sieves (100 mg) also gave lactones 12 in similar yields.
2,3-O-Isopropylidene-4-C-methyl-5-O-trityl-D-ribono-1,4-lactone (12a)
Treatment of 11a (51 mg, 0.11 mmol) with NMO/TPAP, using the procedure reported in Section 4.7, gave 12a (40 mg, 80%): 1 
2,3-O-Isopropylidene-4-C-hexyl-5-O-trityl-D-ribono-1,4-lactone (12b)
Treatment of 11b (37 mg, 0.09 mmol) with NMO/TPAP, using the procedure reported in Section 4. Note: When oxidation of 11c was carried out overnight instead of 6 h, a second minor product ( ∼ 30%) was formed in addition to 12c. The minor product had the following ribosyl peaks: 1 
2,3-O-Isopropylidene-5-O-trityl-4-C-vinyl-D-ribono-1,4-lactone (12d)
Treatment of 11d (100 mg, 0.21 mmol) with NMO/TPAP, using the procedure reported in Section 4.7, gave 12d (90 mg, 95%): 1 , 1H, H5), 3.50 (d, J = 10.3 Hz, H1, H5'), 4.20 (d, J = 5.6 Hz, 1H, H2 5. 2,3-O-Isopropylidene-4-C-4-methoxyphenyl-5-O-trityl-D-ribono-1,4- 
General procedure for detritylation of 4-C-substituted ribono-1,4-lactones
TFA (0.5 mL) and CH 2 Cl 2 (5 mL) were added to a stirred solution of 12 (0.1 mmol) at ambient temperature for 6 h. The volatiles were evaporated and the residue co-evaporated with toluene. The oily residue was partitioned between aqueous NaHCO 3 and CH 2 Cl 2 . The separated organic layer was washed with brine, dried (MgSO 4 ), evaporated and was purified on a silica gel column (hexane/EtOAc, 8:2).
2,3-O-Isopropylidene-4-C-methyl-D-ribono-1,4-lactone (13a)
Treatment of 12a (44 mg, 0.1 mmol) with TFA, using the procedure reported in Section 4.8, gave 13a (13 mg, 66%): 1 8.3. 2,3-O-Isopropylidene-4-C-octyl-D-ribono-1,4-lactone (13c , 1H, H1), 7.25-7.38 (m, 15H, Ar) . 13 
2,3-O-Isopropylidene-4-C-hexyl-5-O-trityl-D-ribofuranose (14b)
LiEt
General procedure for the synthesis of 4-C-substituted S-ribosylhomocyteine lactones 16
Step a. H 2 O (0.24 mL) and tris(2-carboxyethyl)phosphine hydrochloride (88 mg, 0.31 mmol) were added to a stirred solution of N,N'-di(tert-butoxycarbonyl)-l-homocystine di(tert-butyl) ester [13] (160 mg, 0.28 mmol) in anhydrous DMF (2.4 mL) at ambient temperature under Ar atmosphere. After 20 h, the reaction mixture was partitioned between EtOAc, and saturated NaHCO 3 /H 2 O. The aqueous layer was extracted with EtOAc, and the combined organic layer was washed with brine, dried (Na 2 SO 4 ), and concentrated to give N-tert-butoxycarbonyl-l-homocysteine tert-butyl ester (159 mg, 99%) as a colorless oil of sufficient purity to be directly used in the next step.
Step b. LDA (2M/THF and heptanes, 48 μl, 0.96 mmol) was added slowly to a stirred solution of the freshly prepared protected l-homocysteine (29 mg, 0.1 mmol; from step (a) in anhydrous DMF 1.5 ml under Ar atmosphere at 0°C (ice bath). After 30 min, a solution of 15 (0.035 mmol) in DMF (1 mL) was added by a syringe and the mixture was left stirring for 15 min at 0°C then at room temperature for 24 h. The reaction was quenched with NH 4 Cl and the volatiles were evaporated under high vacuum. The residue was partitioned between EtOAc and NaHCO 3 , washed with brine and dried over anhydrous 
General procedure for deprotection of 4-C-substituted S-ribosylhomocyteine lactones
Compound 16 (0.03 mmol) was stirred in TFA (2 mL) at 0°C for 1 h and then at ambient temperature for 3 h. H 2 O (0.1 mL) was then added and stirring was continued for an additional 1 h. Volatiles were evaporated in vacuum below 30°C and the residue was coevaporated with MeCN (2 × 0.5 mL). The crude product was redissolved in deionized water (2.5 mL) and washed with CHCl 3 (2 × 1 mL). The aqueous layer was evaporated in vacuum below 30°C.
S-(4-C-Hexyl-D-ribono-1,4-lactone-5-yl)-l-homocysteine (17b)
Treatment of 16b (17 mg, 0.03 mmol) with TFA, using the procedure reported in Section 4.12, gave 17b (7 mg, 60% 
S-(4-C-Octyl-D-ribono-1,4-lactone-5-yl)-l-homocysteine (17c)
Step a. Treatment of 15c (24 mg, 0.063 mmol) with homocysteinate lithium salt, using the procedure reported in Section 4.11, gave 16c contaminated with protected homocysteine ( Step a) with TFA (2 mL), using the procedure reported in Section 4.12, gave an oily residue that was partitioned between water and CHCl 3 . The aqueous layer was evaporated in vacuum below 30°C and the residue (20 mg) was divided into two portions. Each portion of crude 17c was dissolved in deionized water/MeCN (2.5 mL, 19:1, v/v) and was injected into the Sep-Pak cartridge (C18 classic column). The columns were eluted with deionized water (5 mL), a second portion of deionized water (5 mL) and ethanol (5 mL). The combined water eluents contained mainly Hcy (TLC and 1 H NMR), while the combined ethanol eluents were evaporated in vacuum to give 17c (5 mg, 21% from 15c): 1 
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